Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2001, we proposed to restore this balance using judicious doses of antiangiogenic agents and suggested that this strategy would transiently give rise to tumour vessels with structural and functional phenotypes closer to those of the vessels of nonmalignant tissues — a state we referred to as ‘normalized’ (REF. 61)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“We also suggested that the use of other therapies during this ‘window of normalization’ (REF. 61) would result in better outcomes than if the same agents were given before or after this window.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“Traditional angiogenesis inhibitors mainly block VEGF signaling and prune rather than eradicate tumor vessels.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [78]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“What mechanisms are responsible for this normalization? How can we exploit them? This knowledge will affect the treatment not only of cancer but also of other diseases characterized by abnormal vasculature—such as hemangiomas, arteriovenous malformations, diabetic retinopathy and macular degeneration—for which anti-an…”
BackgroundSelf-citationGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Self-citationLee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Self-citationBaish, J. W., & Jain, R. K. (2000) · PubMed · Cited by 714
Self-citationThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citation
Research works printed but not linked: 6
- Folkman, J. in Harrison's Textbook of Internal Medicine, 15th ed. (eds Braunwald, E. et al.) 517–530 (McGraw-Hill, New York, 2001).
- Kozin, S.V. et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research 60, 6248–6252 (2000).
- Kadambi, A. et al. Vascular endothelial growth factor (VEGF)–C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res. 61, 2404–2408 (2001).
- Lee, C.G. et al. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
- Hansen-Algenstaedt, N. et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
Cited by
Items 701–800 of 1,004
Time-Course Imaging of Therapeutic Functional Tumor Vascular Normalization by Antiangiogenic Agents
Zhang, Q., Bindokas, V. P., Shen, J., Fan, H., Hoffman, R. M., & Xing, H. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0008 · Cited by 49
Okamoto, T., Usuda, H., Tanaka, T., Wada, K., & Shimaoka, M. (2019) · Cancers · doi:10.3390/cancers11020237 · Cited by 50
Alfonso, J. C. L., Köhn‐Luque, A., Stylianopoulos, T., Feuerhake, F., Deutsch, A., & Hatzikirou, H. (2016) · Scientific Reports · doi:10.1038/srep37283 · Cited by 53
Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin
Shen, Y., Li, S., Wang, X., Wang, M., Tian, Q., Yang, J., Wang, B., Wang, B., Liu, P., & Yang, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1366-x · Cited by 51
Zhong, C., Jiang, C., Ni, S., Wang, Q., Cheng, L., Wang, H., Zhang, Q., Liu, W., Zhang, J., Liu, J., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.011 · Cited by 47
Retooling Cancer Nanotherapeutics’ Entry into Tumors to Alleviate Tumoral Hypoxia
Sun, X. J., Ni, N., Ma, Y., Wang, Y., & Leong, D. T. (2020) · Small · doi:10.1002/smll.202003000 · Cited by 47
Shen, R., Peng, L., Zhou, W., Wang, D., Jiang, Q., Ji, J., Hu, F., & Yuan, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.015 · Cited by 48
Quarles, C. C., & Schmainda, K. M. (2007) · Magnetic Resonance in Medicine · doi:10.1002/mrm.21193 · Cited by 48
Barth, R. F., Yang, W., & Coderre, J. A. (2003) · Journal of Neuro-Oncology · doi:10.1007/bf02699934 · Cited by 51
Yonucu, S., Yιlmaz, D., Phipps, C., Unlu, M. B., & Kohandel, M. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005724 · Cited by 46
Matsumoto, S., Saito, K., Takakusagi, Y., Matsuo, M., Munasinghe, J., Morris, H. D., Lizak, M. J., Merkle, H., Yasukawa, K., Devasahayam, N., et al. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5725 · Cited by 46
Limitations of therapies exposed
Casanovas, O. (2012) · Nature · doi:10.1038/484044a · Cited by 49
Lyons, J. A., Sheahan, B. J., Galbraith, S. E., Mehra, R., Atkins, G. J., & Fleeton, M. N. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302889 · Cited by 46
Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab
Weißhardt, P., Trarbach, T., Dürig, J., Paul, A., Reis, H., Tilki, D., Miroschnik, I., Ergün, S., & Klein, D. (2011) · Histochemistry and Cell Biology · doi:10.1007/s00418-011-0898-8 · Cited by 47
ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer
Campbell, N., Greenaway, J. B., Henkin, J., & Petrik, J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0402 · Cited by 46
Carvalho, N. D., Welzel, J., Schuh, S., Themstrup, L., Ulrich, M., Jemec, G. B. E., Holmes, J. D., Kaleci, S., Chester, J., Bigi, L., et al. (2018) · Experimental Dermatology · doi:10.1111/exd.13783 · Cited by 53
Liu, X., Hao, Y., Popovtzer, R., Feng, L., & Liu, Z. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001167 · Cited by 47
RTK Inhibitors in Melanoma: From Bench to Bedside
Sabbah, M., Najem, A., Krayem, M., Awada, A. H., Journé, F., & Ghanem, G. (2021) · Cancers · doi:10.3390/cancers13071685 · Cited by 48
The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)
Massuger, L., Boerman, O., Thomas, C., Sweep, F., & Oei, A. L. M. (1992) · International Journal of Oncology · doi:10.3892/ijo.32.6.1145 · Cited by 49
An in vivo role for Trypanosoma cruzi calreticulin in antiangiogenesis
Molina, M. C., Ferreira, V. P., Valck, C., Aguilar, L., Orellana, J., Rojas, Á., Ramírez‐Toloza, G., Billetta, R., Schwaeble, W., David Lemus, A., et al. (2005) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2004.12.014 · Cited by 46
Arentz, G., Chataway, T., Price, T. J., Izwan, Z., Hardi, G., Cummins, A. G., & Hardingham, J. E. (2011) · Clinical Proteomics · doi:10.1186/1559-0275-8-16 · Cited by 54
Potentiation of radiation‐induced regrowth delay by isosorbide dinitrate in FSaII murine tumors
Jordan, B. F., Beghein, N., Aubry, M., Grégoire, V., & Gallez, B. (2002) · International Journal of Cancer · doi:10.1002/ijc.10786 · Cited by 46
Dana, P., Thumrongsiri, N., Tanyapanyachon, P., Chonniyom, W., Punnakitikashem, P., & Saengkrit, N. (2022) · Nanomaterials · doi:10.3390/nano13010107 · Cited by 53
Ader, I., Gstalder, C., Bouquerel, P., Golzio, M., Andrieu, G. P., Zalvidéa, S., Richard, S., Sabbadini, R. A., Malavaud, B. A., & Cuvillier, O. (2015) · Oncotarget · doi:10.18632/oncotarget.3144 · Cited by 45
Kim, S., Decarlo, L., Cho, G. Y., Jensen, J. H., Sodickson, D. K., Moy, L. P., Formenti, S. C., Schneider, R. J., Goldberg, J. D., & Sigmund, E. E. (2011) · NMR in Biomedicine · doi:10.1002/nbm.1793 · Cited by 48
A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma
Grignol, V. P., Olencki, T. E., Relekar, K., Taylor, C., Kibler, A., Kefauver, C. A., Wei, L., Walker, M. J., Chen, H. X., Kendra, K. L., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821dcefd · Cited by 50
Modification of the tumor microenvironment to enhance immunity
Liao, Y., Schaue, D., & McBride, W. H. (2007) · Frontiers in bioscience · doi:10.2741/2336 · Cited by 49
Shah, D. K., Shin, B. S., Veith, J. M., Tóth, K., Bernacki, R. J., & Balthasar, J. P. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.149443 · Cited by 45
McCormack, D. R., Walsh, A. J., Sit, W. W., Arteaga, C. L., Chen, J., Cook, R. S., & Skala, M. C. (2014) · Biomedical Optics Express · doi:10.1364/boe.5.002247 · Cited by 49
Bello, E., Taraboletti, G., Colella, G., Zucchetti, M., Forestieri, D., Licandro, S. A., Berndt, A., Richter, P., D’Incalci, M., Cavalletti, E., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0275-t · Cited by 45
Toward Normalization of the Tumor Microenvironment for Cancer Therapy
Zheng, J., & Gao, P. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419862352 · Cited by 48
Bullitt, E., Lin, N. U., Smith, J. K., Zeng, D., Winer, E. P., Carey, L. A., Lin, W., & Ewend, M. G. (2007) · Radiology · doi:10.1148/radiol.2453061889 · Cited by 45
Sandström, M., Johansson, M., Bergström, P., Bergenheim, A. T., & Henriksson, R. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9527-3 · Cited by 47
Itasaka, S., Komaki, R. K., Herbst, R. S., Shibuya, K., Shintani, T., Hunter, N. R., Onn, A., Bucana, C. D., Milas, L., Ang, K. K., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.10.030 · Cited by 46
Angiogenesis in pituitary adenomas
Yamada, S., & Takada, K. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10262 · Cited by 47
Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases
Mazitschek, R., & Giannis, A. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.009 · Cited by 45
Saito, Y., Yasunaga, M., Kuroda, J., Koga, Y., & Matsumura, Y. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00806.x · Cited by 45
Aflibercept in the Treatment of Metastatic Colorectal Cancer
Wang, T.-F., & Lockhart, A. C. (2012) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s7432 · Cited by 44
Yang, G., Yang, Y., Liu, R., Li, W., Xu, H., Hao, X., Li, J., Xing, P., Zhang, S., Ai, X., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221082339 · Cited by 45
Tan, K. F., In, L. L. A., & Kumar, P. V. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00202 · Cited by 49
New developments in the medicinal chemistry of carboranes
Satapathy, R., Dash, B. P., Maguire, J. A., & Hosmane, N. S. (2010) · Collection of Czechoslovak Chemical Communications · doi:10.1135/cccc2010050 · Cited by 46
The tumour microenvironment and implications for cancer immunotherapy
Petrulio, C., Kim‐Schulze, S., & Kaufman, H. L. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.7.671 · Cited by 44
Sorace, A. G., Quarles, C. C., Whisenant, J. G., Hanker, A. B., McIntyre, J. O., Sanchez, V. M., & Yankeelov, T. E. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3680-8 · Cited by 45
Fujii, H., Matsuhashi, N., Kitahora, M., Takahashi, T., Hirose, C., Iihara, H., Yamada, Y., Watanabe, D., Ishihara, T., Suzuki, A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0541 · Cited by 45
Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation
Liang, Q., Zhou, L., Li, Y., Liu, J., & Liu, Y. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1927056 · Cited by 46
Dunn, A. E., Dunn, D., Macmillan, A., Whan, R. M., Stait‐Gardner, T., Price, W. S., Lim, M., & Boyer, C. A. (2014) · Polymer Chemistry · doi:10.1039/c4py00150h · Cited by 44
Identification of EpCAM as a Molecular Target of Prostate Cancer Stroma
Mukherjee, S., Richardson, A. M., Rodriguez‐Canales, J., Ylaya, K., Erickson, H. S., Player, A. N., Kawasaki, E. S., Pinto, P. A., Choyke, P. L., Merino, M. J., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090013 · Cited by 46
Subramanian, I. V., Nguyen, T. M. B., Truskinovsky, A. M., Tolar, J., Blazar, B. R., & Ramakrishnan, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3297 · Cited by 47
The Role of Bevacizumab as First-line Therapy for Colon Cancer
Marshall, J. K. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.06.003 · Cited by 44
Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View
Bellati, F., Napoletano, C., Gasparri, M. L., Visconti, V. V., Zizzari, I. G., Ruscito, I., Caccetta, J., Rughetti, A., Panici, P. B., & Nuti, M. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/890758 · Cited by 47
Microvascular morphometrics of the hypophysis and pituitary tumors: From bench to operating theatre
Ieva, A. D., Weckman, A. M., Michele, J. D., Rotondo, F., Grizzi, F., Kovács, K., & Cusimano, M. D. (2013) · Microvascular Research · doi:10.1016/j.mvr.2013.04.009 · Cited by 46
Multimodality imaging and mathematical modelling of drug delivery to glioblastomas
Boujelben, A. H., Watson, M. G., McDougall, S. R., Yen, Y., Gerstner, E. R., Catana, C., Deisboeck, T. S., Batchelor, T. T., Boas, D. A., Rosen, B. R., et al. (2016) · Interface Focus · doi:10.1098/rsfs.2016.0039 · Cited by 45
Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies
Riechelmann, R. P., & Grothey, A. F. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016676703 · Cited by 43
Computational Modeling of Tumor-Induced Angiogenesis
Vilanova, G., Colominas, I., & Gómez, H. (2017) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-016-9199-7 · Cited by 46
B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy
Jiang, L., & Li, N. (2020) · Angiogenesis · doi:10.1007/s10456-020-09729-7 · Cited by 43
Drug resistance: from bacteria to cancer
Patel, H. H., Wu, Z., Chen, Y., Bo, L., & Chen, Z. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00041-4 · Cited by 45
Matharoo‐Ball, B., Ratcliffe, L., Lancashire, L., Ugurel, S., Miles, A. K., Weston, D. J., Rees, R. C., Schadendorf, D., Ball, G., & Creaser, C. S. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700022 · Cited by 43
Novel Immunotherapeutic Strategies of Gastric Cancer Treatment
Amedei, A., Benagiano, M., Bella, C. D., Niccolai, E., & D’Elios, M. M. (2011) · BioMed Research International · doi:10.1155/2011/437348 · Cited by 44
Bullitt, E., Ewend, M. G., Aylward, S., Lin, W., Gerig, G., Joshi, S. C., Jung, I., Muller, K. E., & Smith, J. K. (2004) · Technology in Cancer Research & Treatment · doi:10.1177/153303460400300607 · Cited by 43
Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model
Trédan, O., Lacroix‐Triki, M., Guiu, S., Mouret‐Reynier, M., Barrière, J., Bidard, F., Braccini, A.-L., Mir, O., Villanueva, C., & Barthélémy, P. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0334-9 · Cited by 43
Targeting angiogenesis in endometrial cancer - new agents for tailored treatments
Papa, A., Zaccarelli, E., Caruso, D., Vici, P., Panici, P. B., & Tomao, F. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1116517 · Cited by 42
Zhu, Y., Yu, F., Tan, Y., Hong, Y. K., Meng, T., Liu, Y., Dai, S., Qiu, G., Yuan, H., & Hu, F. (2019) · Theranostics · doi:10.7150/thno.36334 · Cited by 43
Brey, E. M., McIntire, L. V., Johnston, C. M., Reece, G. P., & Patrick, C. (2004) · Annals of Biomedical Engineering · doi:10.1114/b:abme.0000036646.17362.c4 · Cited by 42
Jones‐Bolin, S., Zhao, H. Q., Hunter, K., Klein–Szanto, A. J., & Ruggeri, B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0327 · Cited by 44
Improving delivery of antineoplastic agents with anti‐vascular endothelial growth factor therapy
Yang, A. D., Bauer, T. W., Camp, E. R., Somcio, R., Liu, W., Fan, F., & Ellis, L. M. (2005) · Cancer · doi:10.1002/cncr.20942 · Cited by 45
Angiogenesis in Glioma: Molecular Mechanisms and Roadblocks to Translation
Bögler, O., & Mikkelsen, T. (2003) · The Cancer Journal · doi:10.1097/00130404-200305000-00008 · Cited by 44
Resistance in the anti-angiogenic era: nay-saying or a word of caution?
Sweeney, C. J., Miller, K. D., & Sledge, G. W. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)00007-2 · Cited by 42
Thrombospondins in the tumor microenvironment
Petrik, J., Lauks, S., Garlisi, B., & Lawler, J. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.05.010 · Cited by 42
Emerging nanotechnological approaches to regulating tumor vasculature for cancer therapy
Wang, C., Xu, J., Zhang, Y., & Nie, G. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.017 · Cited by 41
Buckel, L., Advani, S. J., Frentzen, A., Zhang, Q., Yu, Y., Chen, N. G., Ehrig, K., Stritzker, J., Mundt, A. J., & Szalay, A. A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28296 · Cited by 41
Murakami, M., Zhao, S., Zhao, Y., CHOWDHURY, N. F., Yu, W., Nishijima, K., Takiguchi, M., Tamaki, N., & Kuge, Y. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1624 · Cited by 48
Kim, Y., Lee, H., Kim, T., Eisinger‐Mathason, T. S. K., Zhang, A. Y., Schmidt, B. H., Karl, D. L., Nakazawa, M. S., Park, P. J., Simon, M. C., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27666 · Cited by 45
Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies.
Raeve, H. D., Marck, E. V., Camp, B. V., & Vanderkerken, K. (2004) · PubMed · doi:10.14670/hh-19.935 · Cited by 48
Alilou, M., Khorrami, M., Prasanna, P., Bera, K., Gupta, A. B., Viswanathan, V. S., Patil, P. D., Velu, P., Fu, P., Velcheti, V., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq4609 · Cited by 43
Distinct angiogenic and non‐angiogenic growth patterns of lung metastases from renal cell carcinoma
Sardari Nia, P., Hendriks, J., Friedel, G., Van Schil, P., & Van Marck, E. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02800.x · Cited by 41
Ansiaux, R., DeWever, J., Grégoire, V., Féron, O., Jordan, B. F., & Gallez, B. (2009) · Radiation Research · doi:10.1667/rr1744.1 · Cited by 42
Taming Glioblastoma: Targeting Angiogenesis
Wong, E. T., & Brem, S. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1037 · Cited by 43
Yin, J., Dong, F., An, J., Guo, T., Cheng, H., Zhang, J., & Zhang, J. (2024) · Theranostics · doi:10.7150/thno.89306 · Cited by 41
Coutelle, O., Schiffmann, L. M., Liwschitz, M., Brunold, M., Goede, V., Hallek, M. J., Kashkar, H., & Hacker, U. T. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.629 · Cited by 44
Grabner, G., Nöbauer, I., Elandt, K., Kronnerwetter, C., Wöehrer, A., Marosi, C., Prayer, D., Trattnig, S., & Preusser, M. (2011) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2011.08.004 · Cited by 44
How Matrix Properties Control the Self-Assembly and Maintenance of Tissues
Reinhart-King, C. A. (2011) · Annals of Biomedical Engineering · doi:10.1007/s10439-011-0310-9 · Cited by 40
Tellier, C., Desmet, D., Petit, L., Finet, L., Graux, C., Raes, M. J., Féron, O., & Michiels, C. (2015) · Neoplasia · doi:10.1016/j.neo.2014.11.003 · Cited by 40
Baumann, R., Depping, R., Delaperrière, M., & Dunst, J. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192467 · Cited by 44
Cavaco, A. C. M., Rezaei, M., Niland, S., & Eble, J. A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112355 · Cited by 43
Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes
Ribeiro, R. S. G., Belderbos, S., Danhier, P., Gallo, J., Manshian, B. B., Gallez, B., Bañobre‐López, M., Cuyper, M. D., Soenen, S. J., Gsell, W., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s214041 · Cited by 40
Therapeutic Modification of Hypoxia
Horsman, M. R., Sørensen, B. S., Busk, M., & Siemann, D. W. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.08.014 · Cited by 41
Braman, N. M., Prasanna, P., Bera, K., Alilou, M., Khorrami, M., Leo, P., Etesami, M., Vulchi, M., Turk, P., Gupta, A. B., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4148 · Cited by 41
Reichardt, W., Hu‐Lowe, D. D., Torres, D. M., Weissleder, R., & Bogdanov, A. A., Jr. (2005) · Neoplasia · doi:10.1593/neo.05139 · Cited by 41
VEGF-Targeting Therapy for Breast Cancer
Sledge, G. W. (2005) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-006-9005-5 · Cited by 40
Zhou, K., Zhang, J., Wang, Q., Liu, W., Liu, J., Yao, L., Cai, M., Ni, S., Cai, Q.-Y., Wang, G., et al. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0058-y · Cited by 40
Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives
Gacche, R. N. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189020 · Cited by 43
van der Veldt, A. A. M., Smit, E. F., & Lammertsma, A. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00208 · Cited by 39
Phillips, P. G., Yalçın, M., Cui, H., Abdel-Nabi, H. H., Sajjad, M., Bernacki, R. J., Veith, J. M., & Mousa, S. A. (2011) · PubMed · Cited by 39
Does thalidomide prolong survival in dogs with splenic haemangiosarcoma?
Bray, J., Orbell, G., Cave, N., & Munday, J. S. (2017) · Journal of Small Animal Practice · doi:10.1111/jsap.12796 · Cited by 44
Akiyama, Y., Kimura, Y., Enatsu, R., Mikami, T., Wanibuchi, M., & Mikuni, N. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.02.070 · Cited by 40
Defining tumor-associated vascular heterogeneity in pediatric high-grade and diffuse midline gliomas
Wei, X., Meel, M. H., Breur, M., Bugiani, M., Hulleman, E., & Phoenix, T. N. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01243-1 · Cited by 41
Pan, D., Pham, C. T. N., Weilbaecher, K. N., Tomasson, M. H., Wickline, S. A., & Lanza, G. M. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1355 · Cited by 40
Hayano, K., Lee, S. H., Yoshida, H., Zhu, A. X., & Sahani, D. V. (2014) · Academic Radiology · doi:10.1016/j.acra.2014.01.020 · Cited by 39
Quantification of angiogenesis by functional computed tomography in a matrigel model in rats1
Phongkitkarun, S., Kobayashi, S., Kan, Z., Lee, T., & Charnsangavej, C. (2004) · Academic Radiology · doi:10.1016/s1076-6332(03)00728-1 · Cited by 42
Integrin targeted drug and gene delivery
Wang, Z., Chui, W., & Ho, P. C. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903468696 · Cited by 39
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Medicine
- Published
- 2001-09
- Volume
- 7
- Issue
- 9
- Pages
- 987-989
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1603230122
- Cited by
- 2,184
- References
- 26
- Citations by year
- 2026: 58 · 2025: 65 · 2024: 61 · 2023: 88 · 2022: 97 · 2021: 91 · 2020: 93 · 2019: 91 · 2018: 69 · 2017: 94 · 2016: 82 · 2015: 106 · 2014: 94 · 2013: 101 · 2012: 124
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, tumor vasculature normalization, solid tumors, cancer prevention, combination therapy, drug delivery to tumors, tumor vasculature
- MeSH terms
- Blood Vessels, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.